within Pharmacolibrary.Drugs.ATC.L;

model L01XX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.0008583333333333332,
    adminDuration  = 600,
    adminMass      = 260 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00312,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.001,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Altretamine is an oral antineoplastic agent of the alkylating class, primarily used in the past for the treatment of ovarian cancer. It works by interfering with the DNA replication process in cancer cells. Its usage has become less common due to availability of more effective agents, but it may still be used as a third-line therapy for refractory ovarian cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on data from adult female patients with advanced ovarian cancer treated with oral altretamine.</p><h4>References</h4><ol><li><p>Damia, G, &amp; D&#x27;Incalci, M (1995). Clinical pharmacokinetics of altretamine. <i>Clinical pharmacokinetics</i> 28(6) 439–448. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199528060-00002&quot;>10.2165/00003088-199528060-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7656502/&quot;>https://pubmed.ncbi.nlm.nih.gov/7656502</a></p></li><li><p>Hansen, LA, &amp; Hughes, TE (1991). Altretamine. <i>DICP : the annals of pharmacotherapy</i> 25(2) 146–152. DOI:<a href=&quot;https://doi.org/10.1177/106002809102500209&quot;>10.1177/106002809102500209</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1905441/&quot;>https://pubmed.ncbi.nlm.nih.gov/1905441</a></p></li><li><p>Gidwani, B, &amp; Vyas, A (2017). Pharmacokinetic study of solid-lipid-nanoparticles of altretamine complexed epichlorohydrin-β-cyclodextrin for enhanced solubility and oral bioavailability. <i>International journal of biological macromolecules</i> 101 24–31. DOI:<a href=&quot;https://doi.org/10.1016/j.ijbiomac.2017.03.047&quot;>10.1016/j.ijbiomac.2017.03.047</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28315435/&quot;>https://pubmed.ncbi.nlm.nih.gov/28315435</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX03;
